Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Neuro-Oncology|October 23, 2018
Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomasBill H Diplas, Heng Liu, Rui Yang, et al.
Neuro-Oncology|January 23, 2023
Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cellsHeng Liu, Cheng Xu, Bill H Diplas, et al.
Molecular Cancer Research : MCR|April 2, 2020
Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor OlaparibZhaohui Wang, Cheng Xu, Bill H Diplas, et al.
Acta Neuropathologica|November 22, 2018
Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNAChangcun Pan, Bill H Diplas, Xin Chen, et al.
American Journal of Human Genetics|December 29, 2009
Missense mutations in TCF8 cause late-onset Fuchs corneal dystrophy and interact with FCD4 on chromosome 9pS Amer Riazuddin, Norann A Zaghloul, Amr Al-Saif, et al.
Cancer Research|September 24, 2017
<i>Cic</i> Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and DifferentiationRui Yang, Lee H Chen, Landon J Hansen, et al.
Scientific Reports|August 23, 2018
Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cellsKefeng Lei, Ran Sun, Lee H Chen, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2025
Apparent Diffusion Coefficient Magnetic Resonance Imaging as a Predictive Biomarker for Hypoxia, Treatment De-escalation, and Recurrence in Human Papillomavirus-Associated Oropharyngeal CancerJames E Han, Bill H Diplas, Ramesh Paudyal, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signaturesDoga C Gulhan, Vinay Viswanadham, Francesc Muyas, et al.
Neuro-Oncology|January 10, 2026
SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of TelomeresAlexandrea Brown, Laura M Strickland, Elise N Erman, et al.
Pageof 4